Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philip M Clarke

Showing results (1-10 of 85) with videos related to

Pageof 9
Sort By:
Health Economics|March 29, 2002
Testing the convergent validity of the contingent valuation and travel cost methods in valuing the benefits of health carePhilip M Clarke
The Medical Journal of Australia|February 21, 2012
Challenges and opportunities for the Pharmaceutical Benefits SchemePhilip M Clarke
The Medical Journal of Australia|March 19, 2013
The pricing of statins and implications for Pharmaceutical Benefits Scheme expenditurePhilip M Clarke
Health Economics|February 14, 2006
Self-reported health: reliability and consequences for health inequality measurementPhilip M Clarke, Chris Ryan
Social Science & Medicine (1982)|November 29, 2008
Measuring achievement: changes in risk factors for cardiovascular disease in AustraliaPhilip M Clarke, Alison J Hayes
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|December 6, 2005
Estimating utility values for health states of overweight and obese individuals using the SF-36Michael A Kortt, Philip M Clarke
The Medical Journal of Australia|June 10, 2010
Expiry of patent protection on statins: effects on pharmaceutical expenditure in AustraliaPhilip M Clarke, Edmund M Fitzgerald
The Medical Journal of Australia|May 20, 2014
Evaluating the costs and benefits of using combination therapiesPhilip M Clarke, Alex B Avery
Pharmacoeconomics|October 21, 2021
The Value of Genomic Testing: A Contingent Valuation Across Six Child- and Adult-Onset Genetic ConditionsYan Meng, Philip M Clarke, Ilias Goranitis
European Heart Journal|December 26, 2008
Development of life-expectancy tables for people with type 2 diabetesJose Leal, Alastair M Gray, Philip M Clarke
Pageof 9

Showing results (1-10 of 85) with videos related to

Sort By:
Pageof 9
Health Economics|March 29, 2002
Testing the convergent validity of the contingent valuation and travel cost methods in valuing the benefits of health carePhilip M Clarke
The Medical Journal of Australia|February 21, 2012
Challenges and opportunities for the Pharmaceutical Benefits SchemePhilip M Clarke
The Medical Journal of Australia|March 19, 2013
The pricing of statins and implications for Pharmaceutical Benefits Scheme expenditurePhilip M Clarke
Health Economics|February 14, 2006
Self-reported health: reliability and consequences for health inequality measurementPhilip M Clarke, Chris Ryan
Social Science & Medicine (1982)|November 29, 2008
Measuring achievement: changes in risk factors for cardiovascular disease in AustraliaPhilip M Clarke, Alison J Hayes
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|December 6, 2005
Estimating utility values for health states of overweight and obese individuals using the SF-36Michael A Kortt, Philip M Clarke
The Medical Journal of Australia|June 10, 2010
Expiry of patent protection on statins: effects on pharmaceutical expenditure in AustraliaPhilip M Clarke, Edmund M Fitzgerald
The Medical Journal of Australia|May 20, 2014
Evaluating the costs and benefits of using combination therapiesPhilip M Clarke, Alex B Avery
Pharmacoeconomics|October 21, 2021
The Value of Genomic Testing: A Contingent Valuation Across Six Child- and Adult-Onset Genetic ConditionsYan Meng, Philip M Clarke, Ilias Goranitis
European Heart Journal|December 26, 2008
Development of life-expectancy tables for people with type 2 diabetesJose Leal, Alastair M Gray, Philip M Clarke
Pageof 9